Liquidia Corporation Form 8-K Summary
Business Context and Reporting Period
Liquidia Corporation filed a Form 8-K dated December 12, 2023, reporting developments concerning patent litigation and the regulatory status of YUTREPIA (treprostinil) inhalation powder for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Financial Metrics and Liquidity
The filing is limited to an Item 8.01 disclosure regarding legal and intellectual-property matters. It does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material Developments
- United Therapeutics received issuance of U.S. Patent No. 11,826,327 on November 28, 2023. The patent generally covers treating PH-ILD through inhaled administration of treprostinil.
- On November 30, 2023, United Therapeutics amended its Hatch-Waxman patent-infringement complaint in the U.S. District Court for the District of Delaware to add allegations that Liquidia infringes the ’327 Patent by seeking to add the PH-ILD indication to YUTREPIA’s label.
- The litigation also concerns U.S. Patent No. 10,716,793. Liquidia states that neither the ’793 Patent nor the ’327 Patent was issued before YUTREPIA’s original New Drug Application was filed and therefore believes United Therapeutics is not entitled to a statutory 30-month stay for either patent.
- In July 2022, the Patent Trial and Appeal Board ruled that all challenged claims of the ’793 Patent had been shown unpatentable. United Therapeutics’ rehearing request was denied in February 2023.
- United Therapeutics appealed the PTAB decision to the Federal Circuit in April 2023. Oral argument occurred on December 4, 2023, and the appeal remains pending.
Outlook, Risks, and Unusual Items
Liquidia states that it intends to vigorously defend the litigation. The PTAB decision does not override a District Court order providing that YUTREPIA may not be approved based on infringement of the ’793 Patent unless and until the PTAB decision is affirmed on appeal. The pending appeal and amended infringement allegations could affect the timing or availability of YUTREPIA for PAH and PH-ILD indications.
Investor Verification Checklist
- Verify the status and outcome of the Federal Circuit appeal concerning the ’793 Patent.
- Monitor the District Court litigation involving the ’793 and ’327 Patents and any resulting restrictions on YUTREPIA approval or commercialization.
- Confirm whether United Therapeutics can obtain or enforce a statutory 30-month stay relating to either patent.
- Review subsequent regulatory filings for updates to YUTREPIA’s tentative approval, labeling, and PH-ILD indication.